Addus HomeCare (ADUS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Executive summary
The annual meeting will be held virtually on June 10, 2026, with shareholders voting on director elections, auditor ratification, and executive compensation approval.
Shareholders of record as of April 23, 2026, are entitled to vote, with 18,664,776 shares outstanding.
Voting can be done online, by phone, or by mail, and a replay of the meeting will be available for one month.
Voting matters and shareholder proposals
Shareholders will vote on electing two Class II directors, ratifying PricewaterhouseCoopers LLP as auditor for 2026, and approving executive compensation on an advisory basis.
The board recommends voting FOR all proposals.
Shareholder proposals for the 2027 meeting must be submitted by January 4, 2027, and director nominations follow specific bylaw procedures.
Board of directors and corporate governance
The board is divided into three classes, with staggered terms; a majority are independent under Nasdaq rules.
Board leadership combines CEO and Chairman roles, with a Lead Director providing independent oversight.
Four standing committees: Audit, Compensation, Nominating and Corporate Governance, and Government Affairs, all with independent members except Government Affairs.
The board met nine times in 2025, and all directors attended at least 75% of meetings.
No shareholder rights plan is in place.
Latest events from Addus HomeCare
- Q2 2026 revenue rose 8% to $377.4M, with net income up 25.2% and strong cash flow fueling growth.ADUS
Q2 2026 - All agenda items, including director elections and auditor ratification, were approved.ADUS
AGM 2026 - PCS growth, tech adoption, and M&A drive expansion amid stable regulatory and financial outlook.ADUS
RBC Capital Markets Global Healthcare Conference 2026 - Census and hours growth accelerate with tech adoption, supporting balanced expansion and M&A.ADUS
Bank of America Global Healthcare Conference 2026 - Q1 2026 revenue up 7.7%, net income up 18.1%, driven by personal care and hospice growth.ADUS
Q1 2026 - Q3 revenue up 7%, EPS up 13%, Gentiva deal to close Q4, New York exit, liquidity strong.ADUS
Q3 2024 - Q2 revenue up 10.4%, net income up 21.7%, and $350M Gentiva acquisition announced.ADUS
Q2 2024 - Regulatory clarity, strong hiring, and M&A focus drive growth and expansion plans.ADUS
Jefferies 2024 Global Healthcare Conference - Q1 2025 delivered 20% revenue growth and margin gains, led by personal care and acquisitions.ADUS
Q1 2025